about
Identification of PEX7 as the second gene involved in Refsum diseaseThe effectiveness of long-term dietary therapy in the treatment of adult Refsum diseaseA cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 studyThe effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.The Challenges of a Successful Pregnancy in a Patient with Adult Refsum's Disease due to Phytanoyl-CoA Hydroxylase Deficiency.Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.Beyond LDL-C--the importance of raising HDL-C.Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage.Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.Statin therapy in people with diabetes and high-risk patients.The lipid and non-lipid effects of statins.The chemical biology of branched-chain lipid metabolism.New lipid-lowering agents.Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for haemoglobin A1c.Lipid-lowering therapies in development.The origin, global distribution, and functional impact of the human 8p23 inversion polymorphism.A review of the lipid-related effects of fluvastatin.Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?Dyslipidaemia and cardiovascular risk in HIV infection.Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough.Fibrates after the FIELD study: Some answers, more questions.Lipid-altering therapies and the progression of atherosclerotic disease.Homocysteine and cardiovascular disease: a review of the evidence.HIV lipodystrophy and its metabolic consequences: implications for clinical practice.Multiple actions of high-density lipoprotein.CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients.Potential options to treat hypertriglyceridaemia.Lipoprotein a: where are we now?Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.Stroke in systemic lupus erythematosus.Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?Aortic stenosis and lipids: does intervention work?Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy.Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'.New lipid modulating drugs: the role of microsomal transport protein inhibitors.Ideal lipid profile and genes for an extended life span.
P50
Q24338528-F4BBAABE-EE5D-4B07-84C5-96769A2E85D1Q28285268-A7CD825B-1830-492A-BAE7-CC8AB4699632Q28534700-BD27DBB4-2400-4523-ACC9-7639373736B2Q33452910-8362CC72-84E2-43DB-993E-8B8857C164BEQ33627538-9F77BC8B-BC3B-422D-B00A-E7026A5FDF81Q34595932-89D5914F-6F0C-4F10-9C67-D5CB2F712DFAQ34630262-CA67F395-2BB0-47A8-AC6B-828E6EF764EBQ34726392-A69DC83F-2687-4FA0-8B0E-D7F05F33F04CQ34750699-D1D21589-6705-4479-B36B-5F75C2A656ADQ35026444-B10A5C2E-8697-4594-8FF1-10E33B9120FBQ35061869-4CFDEDF1-F26D-4D83-9D68-2DD8AF084776Q35153749-5D09E606-BC85-4992-B55B-3D3B68535C4EQ35157608-5B86B447-6E5A-4CBB-A49C-DA3C0990D457Q35602647-3773DFDE-2B86-4300-931C-A347E724C3C2Q35612198-753A32B1-18D1-4393-955A-42B092444209Q35925570-CD857E7E-B7CA-4005-8C70-23913F6136BFQ36021736-3D81214C-1BA7-4180-B32E-BB008757C325Q36085035-9A291926-DB9E-42E6-AA52-F865FDB5E598Q36085043-3D4895E4-0FDD-4479-B0DE-DDCF76FBC8ACQ36322251-1F291C7D-7C16-473C-89B3-00C4C3588E21Q36374194-59C99D83-0AF8-4653-B72D-F63598AC77E8Q36679599-1F25FAFC-ACE8-48C0-8AEF-1A8AEF9402A2Q36700545-624F6480-8901-4840-9623-BE61CF3DE922Q36892501-9E6D7207-1D60-4A46-B52B-698854F41D67Q37061566-AF55D3C0-3A81-45D6-AB4E-C8C88D3BE1C1Q37180526-FE9B986E-17FB-490F-BE12-91866A244843Q37305423-28B30355-884A-4651-927B-CC974D23053EQ37437952-9E7B7E68-9C08-48DE-B2DE-EB826E343385Q37471265-66E65F82-67C3-4AE8-9030-E6CEBF0BB181Q37474250-06660DB9-2F51-4C93-95DF-071A255C07C8Q37610182-AAEAEDB3-5DFD-42AF-952A-D92B98E86BF2Q37611803-127FD1BF-993B-4612-B951-BFE625FD9EE4Q37677038-077C356E-88D8-4146-96BD-27AE1A241067Q37726912-D9657927-2048-475C-A81C-7817822723AAQ37736230-1B2BA06C-4E16-4E5D-9F68-CCBE0B7CAE6EQ37772033-5B541D85-88DC-4B66-81F2-59DE89914B37Q37790007-20BA6C4F-2027-4C22-82B5-AEE4C995436EQ37815524-ADC8BD7A-57BF-409A-B53F-9EFB41471138Q37854785-66C49E77-EFB8-4AED-BAB2-B5B83C3107AFQ37863439-E800FCE7-658E-4959-BE55-D212455595FF
P50
name
Anthony S Wierzbicki
@ast
Anthony S Wierzbicki
@en
Anthony S Wierzbicki
@nl
type
label
Anthony S Wierzbicki
@ast
Anthony S Wierzbicki
@en
Anthony S Wierzbicki
@nl
prefLabel
Anthony S Wierzbicki
@ast
Anthony S Wierzbicki
@en
Anthony S Wierzbicki
@nl